> 93 Tratamiento sistémico del cáncer de mama BIBLIOGRAFÍA 1. Joy AA, Ghosh M, Fernandes R. Clemons MJ. Systemic treatment approaches in Her-2 negative advanced breast cancer-guidance on the guidelines. Curr Oncol. 2015;22:29-42. 2. Cardoso F, Senkus E, Costa A, Papadopolus E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4). Ann Oncol. 2018;29:1634-57. 3. Chacón López-Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, Martínez Dueñas E, Oliveira M, Seguí Palmer MA, et al. SEOM clinical Guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol. 2019;21(1):31-45. 4. Khosravi-Shahi P, Cabezón-Gutiérrez L, Aparicio Salcedo MI. State of art of advanced triple negative breast cancer. Breast J. 2019;25(5):967-70. 5. Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Medicine. 2019;17:90-9. 6. Hwang S, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019;199:30-57. 7. Bardia A, Mayer I, Vahdat L, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in refractory metastatic Triple negative breast cancer. NEJM. 2019;380:741-51.
RkJQdWJsaXNoZXIy MTQzMjMwMg==